SEC Form 4 · accession 0001209191-16-129187
Eiger BioPharmaceuticals, Inc. · EIGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James H Welch
Officer — Chief Financial Officer
Period of report
Jun 20, 2016
Accepted (ET)
Jun 22, 2016 · 2:55 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001305253
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 20, 2016 | P | 2,000 | $19.7962 | A | 2,000 | D | |
| Common Stock | Jun 22, 2016 | P | 500 | $19.7944 | A | 2,500 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.695 to $19.8752, inclusive. The reporting person undertakes to provide to Eiger BioPharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.